A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Female of non child bearing potential

• Clinical diagnosis of bronchiectasis

• Be sputum producers, with history of chronic expectoration on most days

Exclusion Criteria:

• Concomitant diagnosis of pulmonary disease other than bronchiectasis or COPD

• FEV1 of <30% of predicted normal